| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
|
J Leukoc Biol
|
2013
|
1.90
|
|
2
|
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
|
Cancer Immun
|
2013
|
1.71
|
|
3
|
Pathways and therapeutic targets in melanoma.
|
Oncotarget
|
2014
|
1.17
|
|
4
|
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
|
Clin Cancer Res
|
2015
|
1.09
|
|
5
|
Trial watch: IDO inhibitors in cancer therapy.
|
Oncoimmunology
|
2014
|
1.01
|
|
6
|
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
|
Trends Immunol
|
2016
|
0.96
|
|
7
|
Rational combinations of immunotherapeutics that target discrete pathways.
|
J Immunother Cancer
|
2013
|
0.95
|
|
8
|
Checkpoint modulation in melanoma: an update on ipilimumab and future directions.
|
Curr Oncol Rep
|
2013
|
0.94
|
|
9
|
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
|
Toxins (Basel)
|
2014
|
0.92
|
|
10
|
T and NK cells: two sides of tumor immunoevasion.
|
J Transl Med
|
2013
|
0.89
|
|
11
|
Immune escape mechanisms as a guide for cancer immunotherapy.
|
Clin Cancer Res
|
2014
|
0.88
|
|
12
|
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.
|
Oncoimmunology
|
2014
|
0.87
|
|
13
|
Small molecule drugs with immunomodulatory effects in cancer.
|
Hum Vaccin Immunother
|
2015
|
0.86
|
|
14
|
The past, present and future of immunotherapy against tumor.
|
Transl Lung Cancer Res
|
2015
|
0.85
|
|
15
|
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.
|
Oncoimmunology
|
2016
|
0.84
|
|
16
|
O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.
|
Eur J Med Chem
|
2015
|
0.84
|
|
17
|
Targeting the indoleamine 2,3-dioxygenase pathway in cancer.
|
J Immunother Cancer
|
2015
|
0.84
|
|
18
|
Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer.
|
Front Immunol
|
2013
|
0.82
|
|
19
|
Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy.
|
Front Immunol
|
2014
|
0.80
|
|
20
|
Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery.
|
Int J Neuropsychopharmacol
|
2016
|
0.78
|
|
21
|
Synthesis of [(18) F] 4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide (IDO5L): a novel potential PET probe for imaging of IDO1 expression.
|
J Labelled Comp Radiopharm
|
2015
|
0.78
|
|
22
|
Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.
|
Mol Imaging
|
2016
|
0.78
|
|
23
|
Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.
|
Pharmacogenomics J
|
2015
|
0.77
|
|
24
|
Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection.
|
J Innate Immun
|
2015
|
0.76
|
|
25
|
European Cancer Congress 2015.
|
P T
|
2015
|
0.75
|
|
26
|
Metabolic regulation of immune responses: therapeutic opportunities.
|
J Clin Invest
|
2016
|
0.75
|